#proteindegradation — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #proteindegradation, aggregated by home.social.
-
#Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: https://biotech.industryexaminer.com/amgen-dark-blue-protein-degrader-aml/ #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews
-
#Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: https://biotech.industryexaminer.com/amgen-dark-blue-protein-degrader-aml/ #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews
-
#Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: https://biotech.industryexaminer.com/amgen-dark-blue-protein-degrader-aml/ #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews
-
#Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: https://biotech.industryexaminer.com/amgen-dark-blue-protein-degrader-aml/ #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews
-
#Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: https://biotech.industryexaminer.com/amgen-dark-blue-protein-degrader-aml/ #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews
-
Amgen to acquire Oxford spinout Dark Blue, tucking in a preclinical cancer drug – Endpoints News
Amgen to acquire Oxford spinout Dark Blue, tucking in a preclinical cancer drug Endpoints NewsAmgen swoops on UK cancer…
#NewsBeep #News #Business #Acutemyeloidleukemia #Amgen #Cancerpipeline #DarkBlueTherapeutics #DBT3757 #Deals #GB #JayBradner #Oncologyacquisition #OxfordScienceEnterprises #OxfordUniversity #proteindegradation #R&D #UK #UnitedKingdom
https://www.newsbeep.com/uk/356491/ -
https://www.europesays.com/uk/679295/ Amgen to acquire Oxford spinout Dark Blue, tucking in a preclinical cancer drug – Endpoints News #AcuteMyeloidLeukemia #Amgen #Business #CancerPipeline #DarkBlueTherapeutics #DBT3757 #Deals #JayBradner #OncologyAcquisition #OxfordScienceEnterprises #OxfordUniversity #ProteinDegradation #R&D #UK #UnitedKingdom
-
🧩 The future of drug discovery may depend on how well we understand PROTAC-driven protein partnerships.
🔗 Mapping the energy landscape of PROTAC-mediated protein-protein interactions. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2023.02.049
📚 CSBJ: https://www.csbj.org/
#StructuralBiology #PROTAC #DrugDiscovery #ComputationalBiology #ProteinEngineering #ProteinDegradation #Biopharma #MedicinalChemistry #TargetedTherapies #AIinBiotech #MolecularModeling